Women's Health contents for HCP's
  • Infertility
    • Fertility and reproductive health: focus on AMH
    • More information
    • News – Infertility
  • Pregnancy
    • Preeclampsia
      • Introduction to preeclampsia
      • Diagnostic pathway for screening, prediction and diagnosis of preeclampsia
      • Treatment
      • Key scientific and clinical evidence
      • NICE guidelines
      • More information
    • News – Pregnancy
  • Cervical Cancer
    • Roche Cervical Cancer portfolio
    • Screen with cobas HPV
    • Triage with CINtec Plus Cytology
    • Diagnose with CINtec Histology
    • More information
    • News – Cervical Cancer
  • Osteoporosis
    • Bone Markers for an improved patient management
    • More information
    • News – Osteoporosis
  • News
  • Search
  • Menu Menu
Improving cancer screening in the EU
You are here: Home1 / News2 / News - Cervical Cancer3 / Improving cancer screening in the EU

Improving cancer screening in the EU

News - Cervical Cancer

SAPEA report

Open PDF

 

 

24. June, 2022/by Hana Gasper
Tags: cervical cancer
https://www.rochewomenshealth.com/wp-content/uploads/2020/07/roche_womens_health_logo_white-2-300x109.png 0 0 Hana Gasper https://www.rochewomenshealth.com/wp-content/uploads/2020/07/roche_womens_health_logo_white-2-300x109.png Hana Gasper2022-06-24 06:53:402022-06-25 10:46:22Improving cancer screening in the EU
You might also like
The CERTAIN study results: clinical study excellence with impactful results
p16/Ki-67 and E6/E7 mRNA Accuracy and Prognostic Value in Triaging HPV DNA-Positive Women
Together on the way to eliminate cervical cancer
28th Republic of Croatia Perinatal Mortality Advisory Board in 2019.
Clinical validation of p16/Ki-67 Dual-stained cytology triage of HPV-positive women: Results from the IMPACT trial
Cervical cancer is preventable Launch of the Global Strategy to Accelerate the Elimination of Cervical Cancer

News

  • Improving cancer screening in the EU24. June, 2022 - 6:53
  • Cervical Cancer – The value of diagnostics17. June, 2022 - 9:07
  • The Roche Cervical Cancer Portfolio14. January, 2022 - 13:27
  • p16/Ki-67 and E6/E7 mRNA Accuracy and Prognostic Value in Triaging HPV DNA-Positive Women8. November, 2021 - 16:16
  • Clinical validation of p16/Ki-67 Dual-stained cytology triage of HPV-positive women: Results from the IMPACT trial8. November, 2021 - 15:45
All news

Login with Dialog

Login with DiaLog

Contact

Slovenia

Roche farmacevtska družba d.o.o.
Stegne 13g
SI-1000 Ljubljana
Telephone: +386 1 360 26 00
e-mail: slovenija.info@roche.com

Croatia

Roche d.o.o.
Ulica grada Vukovara 269a
10000 Zagreb
Telephone: +385 1 472 23 33
e-mail: croatia.info@roche.com

Disclaimer
This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin.

This web page is not intended for reporting adverse drug reactions and other safety information.

Slovenia
Please report the suspected adverse reactions that you notice during drug therapy in accordance with the Rules on the Pharmacovigilance of medicinal products for human use (Official Gazette of the Republic of Slovenia, No. 57/14 and 27/17), in the way it is published on the website www.jazmp.si.

Roche contacts for collecting safety information regarding Roche medicinal products: slovenia.drugsafety@roche.com.

Croatia
Please report the suspected adverse reactions that you notice during drug therapy in accordance with the Ordinance on Monitoring Adverse Incidents Related to Medical Devices (Official Gazette, no. 125/13) in the way it is published on the website http://www.halmed.hr/

Roche contacts for collecting safety information regarding Roche medicinal products: croatia.info.ci1@roche.com.

Bosnia and Herzegovina
Please report the suspected adverse reactions that you notice during drug therapy in accordance with the Ordinance On Advertising Of Medicinal Products And Medical Devices (Official Gazette, no. 58/12) in the way it is published on the website http://www.almbih.gov.ba/

Roche contacts for collecting safety information regarding Roche medicinal products: bosnia.drugsafety@roche.com.

© 2018 Roche Slovenija :: Production: Votan komunikacije Nastavitve piškotkov | Cookies list | Slovenia: Legal statement, Privacy policy  |  Croatia: Legal statement, Privacy policy
Scroll to top